| BIOLINERX LTD. DL-,001 |
| USA |
| Gesundheit |
| US09071M3043 / A41038 |
| YP2 (Frankfurt) / BLRX (NASDAQ) |
| FRA:YP2, ETR:YP2, YP2:GR, NASDAQ:BLRX |
| - |
| https://biolinerx.com/ |
|
BioLineRx Ltd. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics primarily targeting oncology and rare diseases. Founded in 2003 and headquartered in Modi'in, Israel, BioLineRx..
>Volltext.. |
| 9.39 Mio. EUR |
| 4.56 Mio. EUR |
| 1.03 Mio. EUR |
| -8.51 Mio. EUR |
| -1.12 Mio. EUR |
| -0.16 EUR |
| 8.79 Mio. EUR |
| 2.82 Mio. EUR |
| -7.05 Mio. EUR |
| 1.72 |
| -95.92% |
| 86.01% |
| - |
| - |
| - |
| - |
| BIOLINERX |
| 05.04.26 |
|